Phase II Study of the combination of Elotuzumab with Lenalidomide as Maintenance Therapy post Autologous Stem Cell Transplant in Patients with Multiple Myeloma
Phase of Trial: Phase II
Latest Information Update: 16 Mar 2018
At a glance
- Drugs Elotuzumab (Primary) ; Lenalidomide (Primary) ; Dexamethasone; Diphenhydramine; Famotidine
- Indications Multiple myeloma
- Focus Therapeutic Use
- 12 Mar 2018 Planned End Date changed from 1 Apr 2019 to 1 Apr 2021.
- 12 Mar 2018 Planned primary completion date changed from 1 Apr 2019 to 1 Apr 2020.
- 12 Dec 2017 Preliminary results (n=55) presented at the 59th Annual Meeting and Exposition of the American Society of Hematology